Scarica l'app Stockscreener
1.55
4.73%
0.07
Actinium Pharmaceuticals Inc Borsa (ATNM) Ultime notizie
Shareholders That Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Should Contact Levi & Korsinsky About Pending Class ActionATNM - ACCESS Newswire
2025-05-12 | Shareholders That Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Should Contact Levi & Korsinsky About Pending Class ActionATNM | NYSEAM:ATNM | Press Release - Stockhouse
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - The Victoria Advocate
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action ... - Bluefield Daily Telegraph
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - GlobeNewswire Inc.
Actinium Pharma (ATNM) Receives Buy Rating with $4.00 Price Targ - GuruFocus
Actinium Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your RightsATNM - PR Newswire
Investors who lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about pending Class ActionATNM - ACCESS Newswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending - GlobeNewswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - GlobeNewswire Inc.
2025-05-10 | Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline | NYSEAM:ATNM | Press Release - Stockhouse
2025-05-09 | Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your RightsATNM | NYSEAM:ATNM | Press Release - Stockhouse
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ATNM Stock News: Actinium Pharmaceuticals, Inc. Investors Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the ATNM Class Action - ACCESS Newswire
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit - Business Wire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium - GlobeNewswire
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a ... - Eagle-Tribune
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
Contact Levi & Korsinsky by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM) - ACCESS Newswire
The Gross Law Firm Notifies Shareholders of Actinium Pharmaceuticals, Inc. (ATNM) of a Class ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies Shareholders of Actinium - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium - PR Newswire
Actinium enrolls first patient on the trial studying Iomab-ACT - TipRanks
Actinium Announces Enrollment of First Patient in the Iomab-ACT - GuruFocus
Actinium Pharmaceuticals (ATNM) Begins Pioneering Iomab-ACT Trial with CAR-T Therapy | ATNM Stock News - GuruFocus
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center - Yahoo Finance
Lost Money on Actinium Pharmaceuticals, Inc.(ATNM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
Renaissance Technologies LLC Purchases 63,400 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Kirby McInerney LLP Urges Investors in Actinium - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ... - Bluefield Daily Telegraph
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc.(ATNM) Shareholders - PR Newswire
JPMorgan Chase & Co. Acquires 110,141 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors ... - Eagle-Tribune
Class Action Filed Against Actinium Pharmaceuticals, Inc. - GlobeNewswire
Press Release Distribution & PR Platform - ACCESS Newswire
ATNM INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In ATNM To Contact Him Directly To Discuss Their Options - PR Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to - Bluefield Daily Telegraph
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation - Kilgore News Herald
Actinium Pharmaceuticals Inc’s results are impressive - uspostnews.com
Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc.(ATNM) - PR Newswire
The Attractiveness of Investing In Actinium Pharmaceuticals Inc (ATNM) is Growing - knoxdaily.com
Actinium Pharmaceuticals Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Market Watch Highlights: Actinium Pharmaceuticals Inc (ATNM) Ends on an Downturn Note at 1.30 - DWinneX
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Actinium Presents Data Showing ATNM-400 is More Efficacious than - GuruFocus
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, A LEADING NATIONAL FIRM, Encourages Actinium - GlobeNewswire
Actinium Pharma (ATNM) Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models - StreetInsider
ATNM Showcases Promising Preclinical AML Results with Actimab-A - GuruFocus
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting - PR Newswire
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Rese - PR Newswire
May 27, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ATNM - PR Newswire
Hematopoietic Stem Cell Transplantation Market to Reach New - openPR.com
ROSEN, A LEADING LAW FIRM, Encourages Actinium - GlobeNewswire
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):